These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 26098424)

  • 21. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
    Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon JJ; Toots M; Ye C; Sticher Z; Kolykhalov AA; Martinez-Sobrido L; Bluemling GR; Natchus MG; Painter GR; Plemper RK
    Science; 2022 Jan; 375(6577):161-167. PubMed ID: 34855509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.
    Jin Z; Tucker K; Lin X; Kao CC; Shaw K; Tan H; Symons J; Behera I; Rajwanshi VK; Dyatkina N; Wang G; Beigelman L; Deval J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7504-16. PubMed ID: 26392512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.
    Bonneux B; Shareef A; Tcherniuk S; Anson B; de Bruyn S; Verheyen N; Thys K; Conceição-Neto N; Van Ginderen M; Kwanten L; Ysebaert N; Vranckx L; Peeters E; Lanckacker E; Gallup JM; Sitthicharoenchai P; Alnajjar S; Ackermann MR; Adhikary S; Bhaumik A; Patrick A; Fung A; Sutto-Ortiz P; Decroly E; Mason SW; Lançois D; Deval J; Jin Z; Eléouët JF; Fearns R; Koul A; Roymans D; Rigaux P; Herschke F
    Antiviral Res; 2024 Jul; 227():105907. PubMed ID: 38772503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA elongation by respiratory syncytial virus polymerase is calibrated by conserved region V.
    Braun MR; Deflubé LR; Noton SL; Mawhorter ME; Tremaglio CZ; Fearns R
    PLoS Pathog; 2017 Dec; 13(12):e1006803. PubMed ID: 29281742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory Syncytial Virus Sequesters NF-κB Subunit p65 to Cytoplasmic Inclusion Bodies To Inhibit Innate Immune Signaling.
    Jobe F; Simpson J; Hawes P; Guzman E; Bailey D
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclopiazonic acid, an inhibitor of calcium-dependent ATPases with antiviral activity against human respiratory syncytial virus.
    Cui R; Wang Y; Wang L; Li G; Lan K; Altmeyer R; Zou G
    Antiviral Res; 2016 Aug; 132():38-45. PubMed ID: 27210812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long Noncoding RNA NRAV Promotes Respiratory Syncytial Virus Replication by Targeting the MicroRNA miR-509-3p/Rab5c Axis To Regulate Vesicle Transportation.
    Li J; Li M; Wang X; Sun M; Ma C; Liang W; Gao X; Wei L
    J Virol; 2020 May; 94(10):. PubMed ID: 32102886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
    N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapies for an old virus: treatment of RSV infections in the 21st Century.
    Lüsebrink J; Schildgen V; Schildgen O
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1125-9. PubMed ID: 19883332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.
    Sourimant J; Rameix-Welti MA; Gaillard AL; Chevret D; Galloux M; Gault E; Eléouët JF
    J Virol; 2015 Apr; 89(8):4421-33. PubMed ID: 25653447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.
    Liuzzi M; Mason SW; Cartier M; Lawetz C; McCollum RS; Dansereau N; Bolger G; Lapeyre N; Gaudette Y; Lagacé L; Massariol MJ; Dô F; Whitehead P; Lamarre L; Scouten E; Bordeleau J; Landry S; Rancourt J; Fazal G; Simoneau B
    J Virol; 2005 Oct; 79(20):13105-15. PubMed ID: 16189012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus M2-1 protein associates non-specifically with viral messenger RNA and with specific cellular messenger RNA transcripts.
    Braun MR; Noton SL; Blanchard EL; Shareef A; Santangelo PJ; Johnson WE; Fearns R
    PLoS Pathog; 2021 May; 17(5):e1009589. PubMed ID: 34003848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus.
    Ouizougun-Oubari M; Pereira N; Tarus B; Galloux M; Lassoued S; Fix J; Tortorici MA; Hoos S; Baron B; England P; Desmaële D; Couvreur P; Bontems F; Rey FA; Eléouët JF; Sizun C; Slama-Schwok A; Duquerroy S
    J Virol; 2015 Nov; 89(21):11129-43. PubMed ID: 26246564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
    Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
    Yoon JJ; Toots M; Lee S; Lee ME; Ludeke B; Luczo JM; Ganti K; Cox RM; Sticher ZM; Edpuganti V; Mitchell DG; Lockwood MA; Kolykhalov AA; Greninger AL; Moore ML; Painter GR; Lowen AC; Tompkins SM; Fearns R; Natchus MG; Plemper RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.
    Bailly B; Richard CA; Sharma G; Wang L; Johansen L; Cao J; Pendharkar V; Sharma DC; Galloux M; Wang Y; Cui R; Zou G; Guillon P; von Itzstein M; Eléouët JF; Altmeyer R
    Sci Rep; 2016 May; 6():25806. PubMed ID: 27194388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.
    Duvall JR; VerPlank L; Ludeke B; McLeod SM; Lee MD; Vishwanathan K; Mulrooney CA; Le Quement S; Yu Q; Palmer MA; Fleming P; Fearns R; Foley MA; Scherer CA
    Antiviral Res; 2016 Jul; 131():19-25. PubMed ID: 27059228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
    Clarke MO; Mackman R; Byun D; Hui H; Barauskas O; Birkus G; Chun BK; Doerffler E; Feng J; Karki K; Lee G; Perron M; Siegel D; Swaminathan S; Lee W
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2484-7. PubMed ID: 25978965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prospects For the Use of Peptides against Respiratory Syncytial Virus].
    Shilovskiy IP; Andreev SM; Kozhikhova KV; Nikolskii AA; Khaitov MR
    Mol Biol (Mosk); 2019; 53(4):541-560. PubMed ID: 31397431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
    Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
    Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.